EXACT Therapeutics AS (OSL:EXTX)

Norway · Delayed Price · Currency is NOK

1.480

+0.050 (3.50%)

At close: Apr 28, 2026

-50.34% (1Y)

Market Cap	93.63M
Revenue (ttm)	59.00K
Net Income (ttm)	-86.97M
Shares Out	63.26M
EPS (ttm)	-1.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,534
Average Volume	98,749
Open	1.460
Previous Close	1.430
Day's Range	1.460 - 1.480
52-Week Range	1.150 - 3.280
Beta	0.22
RSI	40.20
Earnings Date	Apr 8, 2026

About EXACT Therapeutics AS

EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. The company’s ACT platform is under Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for pancreatic, glioblastoma, an... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 11

Stock Exchange Oslo Børs

Ticker Symbol EXTX

Full Company Profile

Financial Performance

Financial Statements

News

EXACT Therapeutics AS Transcript: Investor update

A proprietary ultrasound-activated drug delivery platform is showing promising early results in phase II trials for locally advanced pancreatic cancer, with significant tumor shrinkage and biomarker reduction. Financial runway is secured into 2027, supporting clinical and platform expansion.

2 months ago - Transcripts

EXACT Therapeutics AS Transcript: Status update

A $13 million private placement, led by GE HealthCare, secures funding for a phase II pancreatic cancer trial using Acoustic Cluster Therapy, which has shown strong efficacy and safety signals. Orphan drug designation and strategic partnerships position the company for accelerated approval and significant market opportunity.

1 year ago - Transcripts